CureusDec 2, 2025

Effects of Diabetes and Obesity Treatments on Gum Health and Family Dental Care

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may exhibit properties that could help slow the progression of periodontitis.

Periodontitis is associated with systemic conditions like type 2 diabetes and obesity due to chronic low-grade inflammation.
GLP-1 regulates glucose metabolism and influences body weight and immune function.
GLP-1RAs are utilized for managing type 2 diabetes and obesity and may have additional anti-inflammatory and osteoprotective effects.
Current evidence on the periodontal benefits of GLP-1RAs is primarily indirect and based on preclinical studies.
There is a noted absence of direct randomized clinical trials focusing on specific periodontal outcomes.

Simplified

Periodontitis, an immune-inflammatory disease triggered by a dysbiotic microbial complex, often leads to the destruction of periodontal supporting tissues. It has a bidirectional association with systemic comorbidities, such as type 2 diabetes mellitus (T2DM) and obesity, through chronic low-grade inflammation. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates glucose metabolism, lipid homeostasis, and other vital biological functions. By promoting insulin secretion from pancreatic β-cells, GLP-1 maintains glucose levels, body weight, appetite, and immune function. Accordingly, GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of T2DM and have recently been adopted for obesity management. Furthermore, GLP-1RAs exhibit anti-inflammatory, antioxidant, osteoprotective, and anti-matrix metalloproteinase properties, which may help protect against and slow the progression of periodontitis. These effects are particularly valuable in patients with coexisting diabetes and obesity, providing synergistic benefits for systemic metabolic regulation and periodontal health. However, there is a lack of direct randomized clinical trials evaluating periodontal endpoints, such as bleeding on probing, probing depth, clinical attachment level, and radiographic bone changes. Therefore, any periodontal benefits attributed to GLP-1RAs should be regarded as preliminary evidence, supported mainly by preclinical studies and indirect metabolic effects.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

PubMed

Effects of Diabetes and Obesity Treatments on Gum Health and Family Dental Care

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief